A phase I study of cabozantinib (XL184) in patients with renal cell cancer von Choueiri, T.K., Pal, S.K., McDermott, D.F., Morrissey, S., Ferguson, K.C., Holland, J., Kaelin, W.G., Dutcher, J.P.

Volltext

PD-L1 expression in nonclear-cell renal cell carcinoma von Choueiri, T.K., Fay, A.P., Gray, K.P., Callea, M., Ho, T.H., Albiges, L., Bellmunt, J., Song, J., Carvo, I., Lampron, M., Stanton, M.L., Hodi, F.S., McDermott, D.F., Atkins, M.B., Freeman, G.J., Hirsch, M.S., Signoretti, S.

Volltext

Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up von Fradet, Y., Bellmunt, J., Vaughn, D.J., Lee, J.L., Fong, L., Vogelzang, N.J., Climent, M.A., Petrylak, D.P., Choueiri, T.K., Necchi, A., Gerritsen, W., Gurney, H., Quinn, D.I., Culine, S., Sternberg, C.N., Nam, K., Frenkl, T.L., Perini, R.F., de Wit, R., Bajorin, D.F.

Volltext

Long-term survival results of a randomized phase III trial of vinflunine plus best supportive care versus best supportive care alone in advanced urothelial carcinoma patients after... von Bellmunt, J., Fougeray, R., Rosenberg, J.E., von der Maase, H., Schutz, F.A., Salhi, Y., Culine, S., Choueiri, T.K.

Volltext

Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma von Choueiri, T.K., Motzer, R.J., Rini, B.I., Haanen, J., Campbell, M.T., Venugopal, B., Kollmannsberger, C., Gravis-Mescam, G., Uemura, M., Lee, J.L., Grimm, M.-O., Gurney, H., Schmidinger, M., Larkin, J., Atkins, M.B., Pal, S.K., Wang, J., Mariani, M., Krishnaswami, S., Cislo, P., Chudnovsky, A., Fowst, C., Huang, B., di Pietro, A., Albiges, L.

Volltext

Association of PD-L1 expression on tumor-infiltrating mononuclear cells and overall survival in patients with urothelial carcinoma von Bellmunt, J., Mullane, S.A., Werner, L., Fay, A.P., Callea, M., Leow, J.J., Taplin, M.E., Choueiri, T.K., Hodi, F.S., Freeman, G.J., Signoretti, S.

Volltext

QTc interval prolongation with vascular endothelial growth factor receptor tyrosine kinase inhibitors von Ghatalia, P, Je, Y, Kaymakcalan, M D, Sonpavde, G, Choueiri, T K

Volltext

Bevacizumab increases the risk of arterial ischemia: a large study in cancer patients with a focus on different subgroup outcomes von Schutz, F.A.B., Je, Y., Azzi, G.R., Nguyen, P.L., Choueiri, T.K.

Volltext

Immune checkpoint inhibitors in MITF family translocation renal cell carcinomas and genetic correlates of exceptional responders von Boilève, A, Carlo, M I, Barthélémy, P, Oudard, S, Borchiellini, D, Voss, M H, George, S, Chevreau, C, Landman-Parker, J, Tabone, M-D, Chism, D D, Amin, A, Bilen, M A, Bosse, D, Coulomb-L'hermine, A, Su, Xiaoping, Choueiri, T K, Tannir, Nizar M, Malouf, Gabriel G

Volltext

Outcomes of patients with metastatic renal cell carcinoma that do not meet eligibility criteria for clinical trials von Heng, D.Y.C., Choueiri, T.K., Rini, B.I., Lee, J., Yuasa, T., Pal, S.K., Srinivas, S., Bjarnason, G.A., Knox, J.J., MacKenzie, M., Vaishampayan, U.N., Tan, M.H., Rha, S.Y., Donskov, F., Agarwal, N., Kollmannsberger, C., North, S., Wood, L.A.

Volltext

Primary anti-vascular endothelial growth factor (VEGF)-refractory metastatic renal cell carcinoma: clinical characteristics, risk factors, and subsequent therapy von Heng, D.Y., MacKenzie, M.J., Vaishampayan, U.N., Bjarnason, G.A., Knox, J.J., Tan, M.H., Wood, L., Wang, Y., Kollmannsberger, C., North, S., Donskov, F., Rini, B.I., Choueiri, T.K.

Volltext

The Double Antibody Drug Conjugate (DAD) phase I trial: sacituzumab govitecan plus enfortumab vedotin for metastatic urothelial carcinoma von McGregor, B A, Sonpavde, G P, Kwak, L, Regan, M M, Gao, X, Hvidsten, H, Mantia, C M, Wei, X X, Berchuck, J E, Berg, S A, Ravi, P K, Michaelson, M D, Choueiri, T K, Bellmunt, J

Volltext

Biomarkers: the next therapeutic hurdle in metastatic renal cell carcinoma von Sonpavde, G, Choueiri, T K

Volltext

First-, second-, third-line therapy for mRCC: benchmarks for trial design from the IMDC von Ko, J J, Choueiri, T K, Rini, B I, Lee, J-L, Kroeger, N, Srinivas, S, Harshman, L C, Knox, J J, Bjarnason, G A, MacKenzie, M J, Wood, L, Vaishampayan, U N, Agarwal, N, Pal, S K, Tan, M-H, Rha, S Y, Yuasa, T, Donskov, F, Bamias, A, Heng, D Y C

Volltext

Lenalidomide and pegylated liposomal doxorubicin-based chemotherapy for relapsed or refractory multiple myeloma: safety and efficacy von Baz, R, Walker, E, Karam, MA, Choueiri, TK, Jawde, RA, Bruening, K, Reed, J, Faiman, B, Ellis, Y, Brand, C, Srkalovic, G, Andresen, S, Knight, R, Zeldis, J, Hussein, MA

Volltext

Racial disparities in prostate cancer outcome among prostate-specific antigen screening eligible populations in the United States von Mahal, B.A., Chen, Y.-W., Muralidhar, V., Mahal, A.R., Choueiri, T.K., Hoffman, K.E., Hu, J.C., Sweeney, C.J., Yu, J.B., Feng, F.Y., Kim, S.P., Beard, C.J., Martin, N.E., Trinh, Q.-D., Nguyen, P.L.

Volltext

Risk of infections in renal cell carcinoma (RCC) and non-RCC patients treated with mammalian target of rapamycin inhibitors von Kaymakcalan, M D, Je, Y, Sonpavde, G, Galsky, M, Nguyen, P L, Heng, D Y C, Richards, C J, Choueiri, T K

Volltext

Androgen deprivation therapy and risk of rheumatoid arthritis in patients with localized prostate cancer von Yang, D.D., Krasnova, A., Nead, K.T., Choueiri, T.K., Hu, J.C., Hoffman, K.E., Yu, J.B., Spratt, D.E., Feng, F.Y., Trinh, Q.-D., Nguyen, P.L.

Volltext

Extended follow-up from JAVELIN Renal 101: subgroup analysis of avelumab plus axitinib versus sunitinib by the International Metastatic Renal Cell Carcinoma Database Consortium ris... von Haanen, J.B.A.G., Larkin, J., Choueiri, T.K., Albiges, L., Rini, B.I., Atkins, M.B., Schmidinger, M., Penkov, K., Michelon, E., Wang, J., Mariani, M., di Pietro, A., Motzer, R.J.

Volltext

Incidence and risk of treatment-related mortality in cancer patients treated with the mammalian target of rapamycin inhibitors von Choueiri, T.K., Je, Y., Sonpavde, G., Richards, C.J., Galsky, M.D., Nguyen, P.L., Schutz, F., Heng, D.Y., Kaymakcalan, M.D.

Volltext